Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether ...

Cancer represents a key challenge in medical science, manifesting as a disease where the immune system fails to recognize and eliminate tumor cells. The phenomenon of immune evasion by cancer cells ...

Ipsen (IPSEY) stock rises after the FDA offered Breakthrough Therapy Designation for its antibody therapy IPN60340 in acute myeloid leukemia. Read more here.

Gastrointestinal (GI) cancers represent a complex interplay of genetic mutations, epigenetic alterations, and environmental factors. The initiation and progression of these cancers are influenced by ...

The only potentially curative options for gastric cancer involve endoscopic or surgical resection, with adjunctive systemic ...

Revolution Medicines shows RAS drug optimism with phase 3 catalysts, early-stage valuation, buyout chatter, and competition ...

Zoldonrasib targets KRAS G12D-mutated non-small cell lung cancer, receiving FDA breakthrough therapy designation for its ...

Zoldonrasib is an innovative tri-complex inhibitor that binds to cyclophilin A, creating a complex that selectively recognizes and inhibits the active, oncogenic RAS G12D (ON) mutant. Revolution ...

Targeted therapies are cancer medications that work more selectively than standard chemotherapy medications. They do this by targeting specific molecules or genetic changes in cancer cells in order to ...

-- Results from the Phase 1/2 Trial are a Foundation for the Ongoing Pivotal Study of Soficabtagene Geleucel for R/R T-Cell ALL/ LBL in Pediatric and Adult Patients ST. LOUIS, Mo., Dec. 05, 2025 ...

A team of researchers from the Germans Trias i Pujol Research Institute (IGTP) and Institut Català d'Oncologia (ICO) has studied alterations in the KRAS gene in colorectal cancer by combining genomic ...

AN INSIGHTFUL study suggests that certain oral molecularly targeted cancer therapies may increase the risk of progressive kidney dysfunction over two years, even when an early rise in serum creatinine ...